Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Draws Criticism During Von Eschenbach Confirmation Hearing

This article was originally published in The Tan Sheet

Executive Summary

FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application

You may also be interested in...



FDA Depositions Reveal Crawford’s Prominent Role In Plan B Switch Review

The role of high-level FDA officials in the review of Barr Labs' Rx-to-OTC switch application for Plan B was required by the "high-profile" nature of the NDA, according to Center for Drug Evaluation & Research Director Steven Galson

Plan B Backlash Blocks FDA Commissioner Nomination: Take Two

FDA will not have a permanent commissioner until an actual decision is announced on the proposed Rx to-OTC switch of emergency contraceptive Plan B, if a hold by Senate Democrats is respected

Plan B Draws Criticism During Von Eschenbach Confirmation Hearing

FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS099640

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel